GRPS · Trans American Aquaculture, Inc
$0.00
At close · Aug 11
Going-concern doubt
— flagged Jan 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors, as relative to capital raising activities, create doubt as to our ability to continue as a going concern.”View the 10-Q filed Jan 14, 2026
Market Cap
$180,592
Shares
1.81B
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$331.65K
+226.5%
FY2024
Net Income
-$2.81M
-48.2%
FY2024
Gross Margin
3.02%
+554.4pp
FY2024
Diluted EPS
-$0.00
-22.3%
FY2024
Operating Cash Flow
-$3M
-170.5%
FY2024
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| $16.5K | $331.65K | $101.57K | $49K | $316.11K | — | |
| -$148.79K | $321.62K | $661.59K | $287.13K | $973.42K | — | |
| $165.29K | $10.03K | -$560.02K | -$238.13K | -$657.31K | — | |
| — | 3.02% | -551.34% | -485.97% | -207.93% | — | |
| $599.79K | $846.23K | $864.77K | $148.61K | $232.43K | — | |
| — | $52.29K | $55.59K | — | — | — | |
| $249K | $477.96K | $490.05K | $485.45K | $544.54K | — | |
| -$1.7M | -$1.97M | -$497.14K | -$509.14K | -$512.1K | — | |
| -$2.13M | -$2.81M | -$1.92M | -$895.88K | -$1.4M | $155.2K | |
| $0 | $0 | -$26.94K | $26.94K | $0 | — | |
| -$2.15M | -$2.81M | -$1.89M | -$922.82K | -$1.4M | — | |
| — | -846.96% | -1865.63% | -1883.26% | -443.46% | — | |
| USD/shares | -$0.00 | -$0.00 | -$0.00 | -$0.00 | $0.00 | — |
| USD/shares | -$0.00 | -$0.00 | -$0.00 | -$0.00 | $0.00 | — |
| shares | — | 1.81B | 1.45B | 1.29B | 0 | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2021–FY2024: $0 in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Drug Manufacturers - Specialty & Generic median 2.08×
EV/EBIT
—
Drug Manufacturers - Specialty & Generic median 19.68×
P/E (TTM)
—
Drug Manufacturers - Specialty & Generic median 17.79×
Valuation over time computed as of each quarter's filing date
Key facts
CIK
1990446